Physician profile
Linus J Miller
NPI 1689699894
$19,198.67
in general payments reported to CMS, 2019-2025
60 companies · $2,079 in 2025
The $2,079 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,510 · 2020: $2,285 · 2021: $4,617 · 2022: $2,230 · 2023: $2,884 · 2024: $2,594 · 2025: $2,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,556.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,960.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,618.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,501.73 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,476.78 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $1,245.38 | 2021 | |
| Lilly USA, LLC | $1,105.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,072.38 | 2019-2025 | Otezla, Evenity, Repatha |
| Pfizer INC. | $1,050.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $976.60 | 2021-2025 | |
| Abbvie INC. | $670.57 | 2020-2025 | |
| Dexcom, INC. | $597.34 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor |
| Merck Sharp & Dohme LLC | $565.89 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Idorsia Pharmaceuticals US INC | $510.04 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $504.83 | 2019-2023 | Xarelto |
| Antares Pharma, INC. | $429.01 | 2024-2025 | Xyosted |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linus Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.